View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
September 29, 2013

Boehringer Ingelheim cancer drug shows positive results in Phase III trial

Boehringer Ingelheim's LUME-Lung 1 Phase III clinical trial of novel investigational compound nintedanib has provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer (NSCLC) patients with adenocarcinoma histology.

By Heidi Vella

adenocarcinoma

Boehringer Ingelheim’s LUME-Lung 1 Phase III clinical trial of novel investigational compound nintedanib has provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer (NSCLC) patients with adenocarcinoma histology.

Nintedanib is an investigational compound that is not yet approved or had its safety and efficacy fully established.

It is an oral triple angiokinase inhibitor that targets three receptors crucially involved in angiogenesis and tumour growth. Angiokinase is one of the key processes leading to invasion and metastasis of solid tumours

LUME-Lung 1 showed nintedanib, plus chemotherapy drug docetaxel, provided a statistically significant increase in median overall survival from 10.3 months in the placebo arm to 12.6 months in the nintedanib arm, Boehringer Ingelheim reported.

In addition, the data demonstrated that the earlier adenocarcinoma patients failed first line chemotherapy, the bigger the benefit nintedanib provided. Adenocarcinoma is a cancer of an epithelium that originates in glandular tissue.

"Recent treatment advances for this sizeable patient population have been limited, but we have reached an important milestone with nintedanib."

Compared with the overall adenocarcinoma patient population, patients with advanced adenocarcinoma who progressed within nine months after the start of their first-line treatment achieved a larger median overall survival benefit of three months.

Herlev University Hospital Copenhagen Department of Oncology Dr Anders Mellemgaard said Adenocarcinoma is the most common form of non-small cell lung cancer and the majority of patients with an advanced stage of the disease will ultimately progress after initial therapy, therefore effective second-line treatments are vital.

"Recent treatment advances for this sizeable patient population have been limited, but we have reached an important milestone with nintedanib," Dr Anders said.

"LUME-Lung 1 showed that nintedanib when added to chemotherapy was effective in extending overall survival by 2.3 months for advanced non-small cell lung cancer patients with adenocarcinoma histology and could become an important second-line option for these patients."


Image: Micrograph of an adenocarcinoma showing mucin containing vacuoles. Photo: courtesy of Nephron.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU